openPR Logo
Press release

Download US Blood Cancer Drug Market & Pipeline Analysis 2015 Report

09-15-2017 06:57 AM CET | Health & Medicine

Press release from: Kuick Resarch

Download US Blood Cancer Drug Market & Pipeline Analysis 2015

Pharmaceutical companies have identified the opportunities to generate significant revenues from blood cancer segment in US. Escalating blood cancer incidences, high unmet medical necessities and demand for better therapeutics are some major factors behind growth of US blood cancer market segment. Higher investments have been made by pharmaceutical companies in order to come forth with better therapeutics for generating significant revenues. As a result, numerous therapeutic have been introduced in US market for the successful treatment of blood cancer. Several innovative therapeutics are at different stages of clinical trials which would be introduced in coming years.

Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs.

Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market.

Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase.

"US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights:

* Blood Cancer Incidence & Prevalence
* Blood Cancer Drug Market Overview
* Blood Cancer Drug Market Dynamics
* Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight
* Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs
* Majority Drugs in Phase-I Clinical Trials: 128 Drugs
* Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis
* Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-US-Blood-Cancer-Drug-Market-&-Pipeline-Analysis-2015.php

1. US Blood Cancer Incidence & Prevalence
1.1 Leukemia: Cancer of White Blood Cells (WBC)
1.1.1 Acute Lymphocytic Leukemia (ALL)
1.1.2 Acute Myeloid Leukemia (AML)
1.1.3 Chronic Lymphocytic Leukemia (CLL)
1.1.4 Chronic Myeloid Leukemia (CML)
1.2 Lymphoma: Cancer of Lymphatic System
1.2.1 Hodgkin Lymphoma
1.2.2 Non-Hodgkin Lymphoma (NHL)
1.3 Myeloma

2. US Blood Cancer Drug Market Overview
2.1 Current Market Scenario
2.2 US Blood Cancer Drug Clinical Pipeline Overview

3. US Blood Cancer Drug Market Dynamics
3.1 Favorable Market Parameters
3.2 Commercialization Challenges

4. US Blood Cancer Drug Market Future Prospects

5. Mechanism of Blood Cancer Therapeutics

6. Leukemia Drug Clinical Pipeline by Company & Phase
6.1 Research till Registered
6.2 Discontinued & Suspended Leukemia Drug Clinical Insight

7. Marketed Leukemia Drug Clinical Insight
7.1 Alemtuzumab (Campath®)
7.2 Arsenic Trioxide (Trisenox®)
7.3 Bosutinib (Bosulif®)
7.4 Clofarabine
7.5 Crisantaspase (Erwinaze®)
7.6 Dasatinib (Sprycel®)
7.7 Fludarabine (Fludara®)
7.8 Idarubicin (Idamycin®)
7.9 Imatinib (Gleevec®)
7.10 Irinotecan
7.11 Mercaptopurine Oral Suspension (Purixan™)
7.12 Mitoxantrone (Novantrone®)
7.13 Nilotinib (Tasigna®)
7.14 Obinutuzumab (Gazyva®)
7.15 Ofatumumab (Arzerra®)
7.16 Omacetaxine Mepesuccinate (Synribo®)
7.17 Pegaspargase (Oncaspar®)
7.18 Pentostatin (Nipent®)
7.19 Ponatinib (Iclusig®)
7.20 Sargramostim (Leukine®)
7.21 Tretinoin
7.22 Vincristine Liposomal - Spectrum Pharmaceuticals (Marqibo®)

8. Lymphoma Drug Clinical Pipeline by Company & Phase
8.1 Research till Registered
8.2 Discontinued & Suspended Lymphoma Drug Clinical Insight

9. Marketed Lymphoma Drug Clinical Insight
9.1 Belinostat (Beleodaq®)
9.2 Bexarotene Oral (Targretin®)
9.3 Bexarotene Topical (Targretin®)
9.4 Brentuximab Vedotin (Adcetris®)
9.5 Chlormethine (Valchlor™)
9.6 Denileukin Diftitox (ONTAK®)
9.7 Ibritumomab Tiuxetan (Zevalin®)
9.8 Interferon Alpha-2b (Intron® A)
9.9 Pralatrexate (Folotyn®)
9.10 Romidepsin (Istodax®)
9.11 Vorinostat (Zolinza®)


10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase
10.1 Research till Preregistration
10.2 Discontinued & No Development Reported in Multiple Myeloma Drug Clinical Insight

11. Marketed Multiple Myeloma Drug Clinical Insight
11.1 Carfilzomib (Kyprolis®)
11.2 Doxorubicin Liposomal – ALZA
11.3 Pomalidomide (Pomalyst®)
11.4 Thalidomide (Thalomid®)
11.5 Zoledronic Acid (Zometa®)

12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase
12.1 Research till Preregistration
12.2 Discontinued & Suspended Multiple Blood Cancer Drug Clinical Insight

13. Marketed Multiple Blood Cancer Drug Clinical Insight
13.1 Azacitidine (Vidaza®)
13.2 Bendamustine (Treanda®)
13.3 Bortezomib (Velcade®)
13.4 Cladribine (Leustatin®)
13.5 Decitabine (Dacogen®)
13.6 Ibrutinib (Imbruvica®)
13.7 Idelalisib
13.8 Lenalidomide (Revlimid®)
13.9 Nelarabine (Arranon®)
13.10 Rituximab (Rituxan®)

14. Competitive Landscape
14.1 Actelion Pharmaceuticals
14.2 Amgen
14.3 ARIAD Pharmaceuticals
14.4 Astellas Pharma
14.5 Baxter BioScience
14.6 Bayer HealthCare Pharmaceuticals Inc.
14.7 Biogen Idec
14.8 Bristol-Myers Squibb
14.9 CASI Pharmaceuticals
14.10 Celera Genomics Group
14.11 Celgene Corporation
14.12 Eisai
14.13 Genmab
14.14 Gilead Sciences
14.15 GlaxoSmithKline
14.16 Hospira
14.17 Johnson & Johnson
14.18 Millennium Pharmaceuticals
14.19 Nova Laboratories
14.20 Novartis
14.21 Onxeo SA
14.22 Onyx Pharmaceuticals
14.23 Otsuka Pharmaceutical
14.24 Pfizer
14.25 Roche
14.26 Scripps Clinic
14.27 Seattle Genetics
14.28 SRI International
14.29 Southern Research Institute
14.30 Tekmira Pharmaceuticals Corporation
14.31 Teva Pharmaceutical Industries
14.32 Yakult Honsha

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Download US Blood Cancer Drug Market & Pipeline Analysis 2015 Report here

News-ID: 718402 • Views: 254

More Releases from Kuick Resarch

TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026
Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 1 Drugs • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026 • Future Market Assessment By Indication Till 2026 • Ongoing Clinical Trials Assessment by Status, Phase & Region • Key Market Dynamics • Competitor Landscape Download Report:
Global Fibroblast Growth Factor Receptor FGFR Cancer Therapy Market Clinical Tri …
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026 Report Highlights: • Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 • Role of FGFR Inhibitors in Cancer Therapy • Global FGFR Market Assessment (US$) by Region and Cancer Type • Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) • Dosage and Drug Price Insight on Approved FGFR Inhibitors • Comprehensive Clinical Trials Insight by Company, Country, Phase and
Clinical Trials Advances And Challenges in Bispecific and Trispecific Antibodies …
In recent years, healthcare sector has witnessed emergence of several promising multispecific antibodies which have revolutioned the management of several chronic disorders, including cancer. Multispecific antibodies consist of large family of molecules which recognizes trwo or more different antigens or epitopes. The robust idea of multispecific antibodies has led to the development of several bispecific and trispecific antibodies for the treatment of cancer and other diseases. Till date, three bispecific
Global CFTR Modulators Market Opportunity Clinical Trials Insight 2026
“Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” Report Highlights: • Global CFTR Modulators Market Opportunity: > US$ 20 Billion • Global CFTR Modulators Market Growth: 42% CAGR (2017 -2020) • Global CFTR Modulators Market Growth In 2020: 55% • Global CFTR Modulators Pipeline: 30 Drug • Commercially Available Bispecific Antibodies: 4 Drugs • Trikafta Market Share 2020: > 50% Download Report: https://www.kuickresearch.com/report-global-cystic-fibrosis-cftr-modulators-therapeutics-market-size-vertex-trikafta-cftr-potentiators-clinical-trials-research “Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” provides

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning